Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: A process for catalytic hydrogenation of aromatic amines can be performed. The aromatic amines can be methylenedianiline and/or tolylenediamine. The ring-hydrogenated equivalents can be obtained by contacting an input product, which have the aromatic amines and impurities, such as, alcohols, glycols, polyols, organic acids and/or water, with hydrogen in the presence of a catalyst. The catalyst can be platinum, palladium, rhodium, ruthenium, nickel, cobalt and/or iron. The catalyst is applied to a support, wherein the input product that has aromatic amines result from a PU decomposition process and contains impurities from this decomposition process.

Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.

Abstract: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a mixture of alkoxylated monoalcohols, where the alkoxylated monoalcohol or, if a mixture of alkoxylated monoalcohols is present, at least one alkoxylated monoalcohol in the mixture comprises at least one oxypropylene unit.